Weekly GLP-1 Receptor Agonists in Obese Individuals Without Diabetes

The study examined the efficacy of weekly GLP-1 receptor agonists in patients with obesity who do not have diabetes. The tested medications were dulaglutide, semaglutide, and tirzepatide. The study was conducted at Zagazig University and Najran University. The objective was to evaluate the safety and efficacy of these drugs in treating obesity without the presence of diabetes. The study has been completed and its results are available. These medications belong to the class of GLP-1 receptor agonists, which are used for weight regulation.